An isolated monoclonal antibody or fragment antigen binding thereof, wherein said antibody or binding fragment antigen specifically binds to the protein human cMet, said antibody or fragment antigen binding variable domain heavy chain comprising comprising CDR3, CDR2 and CDR1 domain and a variable light chain CDR3 comprising, CDR2 and CDR1, wherein: the variable heavy chain CDR3 sequence is SEQ ID NO: 21 the variable heavy chain CDR2 sequence is selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 83 and SEQ ID NO: 84 and the variable sequence heavy chain CDR1 is SEQ ID NO: 19 and the light chain variable domain includes a combination of CDRs selected from the following: (i) the variable light chain CDR3 sequence is SEQ ID NO: 33 variable sequence light chain CDR2 is SEQ ID NO: 32 variable sequence light chain CDR1 is SEQ ID NO: 31 or (ii) the variable light chain CDR3 sequence is SEQ ID NO: 145 variable sequence light chain CDR2 is SEQ ID NO: 32 variable sequence light chain CDR1 is SEQ ID NO: 144 or (iii) the variable light chain CDR3 sequence is SEQ ID NO: 146 variable sequence light chain CDR2 is SEQ ID NO: 32 variable sequence light chain CDR1 is SEQ ID NO: 31 or (iv) the variable light chain CDR3 sequence is SEQ ID NO: 147 variable sequence light chain CDR2 is SEQ ID NO: 32 variable sequence light chain CDR1 is SEQ ID NO: 144 or (v) the variable light chain CDR3 sequence is SEQ ID NO: 148 variable sequence light chain CDR2 is SEQ ID NO: 32 variable sequence light chain CDR1 is SEQ ID NO: 144.Un anticuerpo monoclonal aislado o fragmento de unión al antígeno del mismo, donde dicho anticuerpo o fragmento de unión al antígeno se une específicamente a la proteína c-Met humana, comprendiendo dicho anticuerpo o fragmento de unión al antígeno un dominio variable de cadena pesada que comprende CDR3, CDR2 y CDR1 y un domino variable de cadena ligera que comprende CDR3, CDR2 y CDR1, donde: la secuencia variable CDR3 de cadena pesada es SEQ ID NO: 21 la secuenc
